Recent Quotes (30 days)

You have no recent quotes
chg | %

Collegium Pharmaceutical Inc  

(Public, NASDAQ:COLL)   Watch this stock  
Find more results for COLL
0.00 (0.00%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 7.37 - 17.73
Open     -
Vol / Avg. 300.00/834,690.00
Mkt cap 558.12M
P/E     -
Div/yield     -
EPS -2.97
Shares 32.56M
Beta     -
Inst. own 98%
Nov 8, 2017
Q3 2017 Collegium Pharmaceutical Inc Earnings Call - Webcast
Nov 8, 2017
Q3 2017 Collegium Pharmaceutical Inc Earnings Release
Sep 25, 2017
Collegium Pharmaceutical Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 11, 2017
Collegium Pharmaceutical Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -110.99% -5504.15%
Operating margin -112.38% -5498.66%
EBITD margin - -5460.37%
Return on average assets -43.04% -72.52%
Return on average equity -55.48% -85.62%
Employees 234 -
CDP Score - -


780 Dedham St Ste 800
CANTON, MA 02021-1417
United States - Map
+1-781-7133699 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Officers and directors

Michael Thomas Heffernan Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Paul Brannelly CPA Chief Financial Officer, Executive Vice President
Age: 42
Bio & Compensation  - Reuters
Joseph J. Ciaffoni Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Douglas R. Carlson Vice President - Corporate Development
Bio & Compensation  - Reuters
Alison B Fleming Vice President of Product Development
Age: 40
Bio & Compensation  - Reuters
Ernest A. Kopecky Ph.D. Vice President - Clinical Development and Head of Neuroscience
Age: 48
Bio & Compensation  - Reuters
Kevin OKeeffe Vice President - Market Access and Trade
Bio & Compensation  - Reuters
Steven Passik Ph.D. Vice President - Scientific Affairs, Education and Policy
Bio & Compensation  - Reuters
Said Saim Ph.D. Vice President of Pharmaceutical Development
Age: 57
Bio & Compensation  - Reuters
John Weet Ph.D. Vice President - Regulatory Affairs and Quality Assurance
Bio & Compensation  - Reuters